欧洲七个电子健康数据库中骨质疏松症药物的使用分析
本研究利用英国、意大利、荷兰、丹麦、西班牙和德国的七个欧洲电子健康数据库,纳入2018年1月1日至2022年1月31日期间新使用双膦酸盐、地舒单抗、特立帕肽或选择性雌激素受体调节剂(SERM)的成人患者,描述其用药特征与用药模式。患者多为女性、年龄较大、患有高血压;所有药物和数据库的持续用药率均随时间下降,口服药物尤为明显;换药相对少见,且多发生在治疗前6个月。
要点
- 阿仑膦酸是最常起始使用的骨质疏松药物,其持续用药率6个月为52-73%,12个月降至29-53%。
- 其他口服双膦酸盐持续用药率6个月为50-66%,12个月降至30-44%。
- 地舒单抗持续用药率6个月为50-85%、12个月为30-63%;特立帕肽6个月为40-75%、12个月降至21-54%。
核心结论
- 研究结果显示骨质疏松症药物的持续用药不理想,且在不同数据库间存在差异,治疗换药相对少见。
研究设计与样本
- 队列研究,使用英国、意大利、荷兰、丹麦、西班牙和德国的七个欧洲电子健康数据库。
- 纳入年龄≥18岁、在各自数据库注册≥1年、新使用骨质疏松症药物的成人。
- 研究期间为2018年1月1日至2022年1月31日。
主要发现
- 患者最常起始使用阿仑膦酸;患者多为女性、年龄较大、患有高血压。
- 阿仑膦酸持续用药率6个月为52-73%,12个月为29-53%。
- 其他口服双膦酸盐持续用药率6个月为50-66%,12个月为30-44%。
- SERM持续用药率6个月为40-73%,12个月为25-59%。
- 地舒单抗持续用药率6个月为50-85%、12个月为30-63%;特立帕肽6个月为40-75%、12个月为21-54%。
临床怎么用
- 作者认为研究结果有助于医疗保健提供者集中资源改善特定骨质疏松症治疗的持续用药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We studied the characteristics of patients prescribed osteoporosis medication and patterns of use in European databases. Patients were mostly female, older, had hypertension. There was suboptimal persistence particularly for oral medications. Our findings would be useful to healthcare providers to focus their resources on improving persistence to specific osteoporosis treatments. PURPOSE: To characterise the patients prescribed osteoporosis therapy and describe the drug utilization patterns. METHODS: We investigated the treatment patterns of bisphosphonates, denosumab, teriparatide, and selective estrogen receptor modulators (SERMs) in seven European databases in the United Kingdom, Italy, the Netherlands, Denmark, Spain, and Germany. In this cohort study, we included adults aged ≥ 18 years, with ≥ 1 year of registration in the respective databases, who were new users of the osteoporosis medications. The study period was between 01 January 2018 to 31 January 2022. RESULTS: Overall, patients were most commonly initiated on alendronate. Persistence decreased over time across all medications and databases, ranging from 52-73% at 6 months to 29-53% at 12 months for alendronate. For other oral bisphosphonates, the proportion of persistent users was 50-66% at 6 months and decreased to 30-44% at 12 months. For SERMs, the proportion of persistent users at 6 months was 40-73% and decreased to 25-59% at 12 months. For parenteral treatment groups, the proportions of persistence with denosumab were 50-85% (6 month), 30-63% (12 month) and with teriparatide 40-75% (6 month) decreasing to 21-54% (12 month). Switching occurred most frequently in the alendronate group (2.8-5.8%) and in the teriparatide group (7.1-14%). Switching typically occurred in the first 6 months and decreased over time. Patients in the alendronate group most often switched to other oral or intravenous bisphosphonates and denosumab. CONCLUSION: Our results show suboptimal persistence to medications that varied across different databases and treatment switching was relatively rare.
引用
- Tan EH, Robinson DE, Jödicke AM, et al. Drug utilization analysis of osteoporosis medications in seven European electronic health databases. Osteoporos Int. 2023. PMID: 37436441. doi:10.1007/s00198-023-06837-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。